X4 Pharmaceuticals shares are trading higher after the company announced FDA acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM syndrome.
Portfolio Pulse from Benzinga Newsdesk
X4 Pharmaceuticals announced that the FDA has accepted with Priority Review its U.S. New Drug Application (NDA) for Mavorixafor in WHIM syndrome. This news has led to a rise in the company's share prices.
October 31, 2023 | 6:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
X4 Pharmaceuticals' shares are trading higher following the FDA's acceptance with Priority Review of its NDA for Mavorixafor in WHIM syndrome.
The FDA's acceptance of X4 Pharmaceuticals' NDA for Mavorixafor with Priority Review is a significant positive development for the company. This indicates that the FDA sees the drug as a high priority, which could lead to faster approval and market entry. This news has already led to a rise in the company's share prices, and it could continue to have a positive impact in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100